Topic Hub

Alirocumab — Off-Label Uses

4 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.

4articles

34keywords mapped

2026-05-26latest review

Explore

Alirocumab — Off-Label Uses library

Showing 4 of 4 clinical reviews.

Dosing & Monitoring2026-05-26

Praluent (Alirocumab) for ASCVD Secondary Prevention: Dosing Protocol and Evidence

Evidence-based guide to alirocumab (Praluent) for ASCVD secondary prevention, including dosing protocols, ODYSSEY OUTCOMES trial data, and clinical guidelines for PCSK9 inhibitor use.

Read clinical review

Safety2026-05-26

Praluent (Alirocumab) for ASCVD Secondary Prevention: Off-Label Evidence, Risks, and Tradeoffs

A clinical review of alirocumab (Praluent) used off-label for ASCVD secondary prevention, including ODYSSEY OUTCOMES trial data, risk-benefit analysis, FDA-approved indications, and practical prescribing guidance.

Read clinical review

Dosing & Monitoring2026-05-26

Praluent (Alirocumab) for Familial Hypercholesterolemia: Monitoring Guide

Evidence-based monitoring protocol for alirocumab (Praluent) in familial hypercholesterolemia (FH), including lipid panel timing, safety labs, injection-site surveillance, and when to adjust therapy.

Read clinical review

Safety2025-07-10

Praluent for FH: Off-Label Use, Evidence, Risks, and Tradeoffs

A detailed clinical guide to alirocumab (Praluent) for familial hypercholesterolemia, covering FDA-approved indications, off-label status, evidence quality, dosing, risks, and how it compares to evolocumab.

Read clinical review